The stock of Ginkgo Bioworks Holdings Inc (DNA) has seen a -10.82% decrease in the past week, with a -26.97% drop in the past month, and a -37.18% decrease in the past quarter. The volatility ratio for the week is 6.96%, and the volatility levels for the past 30 days are at 8.36% for DNA. The simple moving average for the past 20 days is -13.90% for DNA’s stock, with a -39.56% simple moving average for the past 200 days.
Is It Worth Investing in Ginkgo Bioworks Holdings Inc (NYSE: DNA) Right Now?
The 36-month beta value for DNA is also noteworthy at 1.35. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 1 rating it as “sell.”
The public float for DNA is 36.98M, and at present, short sellers hold a 26.98% of that float. The average trading volume of DNA on April 02, 2025 was 1.66M shares.
DNA) stock’s latest price update
The stock price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has jumped by 4.78 compared to previous close of 5.66. Despite this, the company has seen a fall of -10.82% in its stock price over the last five trading days. zacks.com reported 2025-04-01 that The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at -40.46% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.54% of loss for the given period.
Volatility was left at 8.36%, however, over the last 30 days, the volatility rate increased by 6.96%, as shares sank -29.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.44% lower at present.
During the last 5 trading sessions, DNA fell by -11.95%, which changed the moving average for the period of 200-days by -68.32% in comparison to the 20-day moving average, which settled at $6.88. In addition, Ginkgo Bioworks Holdings Inc saw -39.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Che Austin, who proposed sale 99 shares at the price of $5.45 back on Apr 02 ’25. After this action, Che Austin now owns shares of Ginkgo Bioworks Holdings Inc, valued at $540 using the latest closing price.
Che Austin, the Officer of Ginkgo Bioworks Holdings Inc, proposed sale 99 shares at $5.69 during a trade that took place back on Apr 01 ’25, which means that Che Austin is holding shares at $563 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -2.38 for the present operating margin
- 0.68 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -2.41. The total capital return value is set at -0.43. Equity return is now at value -60.34, with -35.96 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 0.61. The interest coverage ratio of the stock is -5749.91.
Currently, EBITDA for the company is -484.39 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1.01. The receivables turnover for the company is 10.39for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.62.
Conclusion
In summary, Ginkgo Bioworks Holdings Inc (DNA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
